{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:43:18Z","timestamp":1789166598033,"version":"build-2803163510"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T00:00:00Z","timestamp":1683158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Asciminib is an allosteric high-affinity tyrosine kinase inhibitor (TKI) of the BCR-ABL1 protein kinase. This kinase is translated from the Philadelphia chromosome in chronic myeloid leukemia (CML). Marketing authorization for asciminib was granted on August 25, 2022 by the European Commission. The approved indication was for patients with Philadelphia chromosome-positive CML in the chronic phase which have previously been treated with at least 2 TKIs. Clinical efficacy and safety of asciminib were evaluated in the open-label, randomized, phase III ASCEMBL study. The primary endpoint of this trial was major molecular response (MMR) rate at 24 weeks. A significant difference in MRR rate was shown between the asciminib treated population and the bosutinib control group (25.5% vs. 13.2%, respectively, P\u2005=\u2005.029). In the asciminib cohort, adverse reactions of at least grade 3 with an incidence\u2005\u2265\u20055% were thrombocytopenia, neutropenia, increased pancreatic enzymes, hypertension, and anemia. The aim of this article is to summarize the scientific review of the application which led to the positive opinion by the European Medicines Agency\u2019s Committee for Medicinal Products for Human Use.<\/jats:p>","DOI":"10.1093\/oncolo\/oyad119","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T18:27:54Z","timestamp":1683224874000},"page":"628-632","source":"Crossref","is-referenced-by-count":4,"title":["The EMA Assessment of Asciminib for the Treatment of Adult Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Who Were Previously Treated With at Least Two Tyrosine Kinase Inhibitors"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3541-9242","authenticated-orcid":false,"given":"C Mircea S","family":"Tesileanu","sequence":"first","affiliation":[{"name":"Oncology and Hematology Office, European Medicines Agency , Amsterdam , The Netherlands"},{"name":"Department of Neurology, The Brain Tumor Center, Erasmus MC Cancer Institute , Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Michaleas","sequence":"additional","affiliation":[{"name":"Oncology and Hematology Office, European Medicines Agency , Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio","family":"Gonzalo Ruiz","sequence":"additional","affiliation":[{"name":"Oncology and Hematology Office, European Medicines Agency , Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Segundo","family":"Mariz","sequence":"additional","affiliation":[{"name":"Orphan Medicines Office, European Medicines Agency , Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babs O","family":"Fabriek","sequence":"additional","affiliation":[{"name":"Medicines Evaluation Board , Utrecht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula B","family":"van Hennik","sequence":"additional","affiliation":[{"name":"Medicines Evaluation Board , Utrecht , The Netherlands"},{"name":"Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency , Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutta","family":"Dedorath","sequence":"additional","affiliation":[{"name":"Federal Institute for Drugs and Medical Devices , Bonn , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna","family":"Dekic","sequence":"additional","affiliation":[{"name":"Federal Institute for Drugs and Medical Devices , Bonn , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Unkrig","sequence":"additional","affiliation":[{"name":"Federal Institute for Drugs and Medical Devices , Bonn , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Brandt","sequence":"additional","affiliation":[{"name":"Federal Institute for Drugs and Medical Devices , Bonn , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Koenig","sequence":"additional","affiliation":[{"name":"Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency , Amsterdam , The Netherlands"},{"name":"Federal Institute for Drugs and Medical Devices , Bonn , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Enzmann","sequence":"additional","affiliation":[{"name":"Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency , Amsterdam , The Netherlands"},{"name":"Federal Institute for Drugs and Medical Devices , Bonn , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5157-4376","authenticated-orcid":false,"given":"Julio","family":"Delgado","sequence":"additional","affiliation":[{"name":"Oncology and Hematology Office, European Medicines Agency , Amsterdam , The Netherlands"},{"name":"Department of Hematology, Hospital Clinic , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pignatti","sequence":"additional","affiliation":[{"name":"Oncology and Hematology Office, European Medicines Agency , Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,5,4]]},"reference":[{"issue":"6","key":"2023070520003801200_CIT0001","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ajh.25792","article-title":"Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring","volume":"95","author":"Jabbour","year":"2020","journal-title":"Am J Hematol"},{"issue":"5405","key":"2023070520003801200_CIT0002","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"issue":"6105","key":"2023070520003801200_CIT0003","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/325631a0","article-title":"A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia","volume":"325","author":"Kurzrock","year":"1987","journal-title":"Nature"},{"issue":"15","key":"2023070520003801200_CIT0004","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1056\/NEJM198810133191506","article-title":"The molecular genetics of Philadelphia chromosome-positive leukemias","volume":"319","author":"Kurzrock","year":"1988","journal-title":"N Engl J Med"},{"issue":"25","key":"2023070520003801200_CIT0005","doi-asserted-by":"crossref","first-page":"11746","DOI":"10.1073\/pnas.92.25.11746","article-title":"The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation","volume":"92","author":"Raitano","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2023070520003801200_CIT0006","first-page":"247","article-title":"Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia","volume":"13","author":"Shuai","year":"1996","journal-title":"Oncogene"},{"issue":"49","key":"2023070520003801200_CIT0007","doi-asserted-by":"crossref","first-page":"31704","DOI":"10.1074\/jbc.271.49.31704","article-title":"P210 and P190(BCR\/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members","volume":"271","author":"Ilaria","year":"1996","journal-title":"J Biol Chem"},{"issue":"1","key":"2023070520003801200_CIT0008","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1172\/JCI9083","article-title":"Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia","volume":"105","author":"Druker","year":"2000","journal-title":"J Clin Invest"},{"issue":"14","key":"2023070520003801200_CIT0009","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"issue":"9","key":"2023070520003801200_CIT0010","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"issue":"3","key":"2023070520003801200_CIT0011","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/cncr.24066","article-title":"Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"issue":"9976","key":"2023070520003801200_CIT0012","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic myeloid leukaemia","volume":"385","author":"Apperley","year":"2015","journal-title":"Lancet"},{"issue":"10","key":"2023070520003801200_CIT0013","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.6004\/jnccn.2019.7303","article-title":"Long-term patterns of oral anticancer agent adoption, duration, and switching in patients with CML","volume":"17","author":"Banegas","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"2023070520003801200_CIT0014","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"7647","key":"2023070520003801200_CIT0015","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"key":"2023070520003801200_CIT0016","author":"EMA\u2019s Committee for Medicinal Products for Human Use (CHMP)","year":"2022"},{"key":"2023070520003801200_CIT0017","author":"EMA\u2019s Committee for Medicinal Products for Human Use (CHMP)","year":"2022"},{"key":"2023070520003801200_CIT0018","author":"EMA\u2019s Committee for Orphan Medicinal Products (COMP)","year":"2022"},{"key":"2023070520003801200_CIT0019","author":"EMA\u2019s Committee for Orphan Medicinal Products (COMP)","year":"2020"},{"key":"2023070520003801200_CIT0020","author":"EMA\u2019s Committee for Medicinal Products for Human Use (CHMP)","year":"2022"},{"issue":"20","key":"2023070520003801200_CIT0021","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in \u00adtreatment-naive chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"2023070520003801200_CIT0022","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"issue":"10","key":"2023070520003801200_CIT0023","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"2023070520003801200_CIT0024","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"2023070520003801200_CIT0025","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"issue":"1","key":"2023070520003801200_CIT0026","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/ajh.24247","article-title":"Chronic myeloid leukemia: second-line drugs of choice","volume":"91","author":"Gambacorti-Passerini","year":"2016","journal-title":"Am J Hematol"},{"issue":"4","key":"2023070520003801200_CIT0027","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"issue":"6","key":"2023070520003801200_CIT0028","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0092-8674(03)00194-6","article-title":"Structural basis for the autoinhibition of c-Abl tyrosine kinase","volume":"112","author":"Nagar","year":"2003","journal-title":"Cell"},{"issue":"1","key":"2023070520003801200_CIT0029","doi-asserted-by":"crossref","first-page":"103580","DOI":"10.1016\/j.critrevonc.2022.103580","article-title":"Development of asciminib, a novel allosteric inhibitor of BCR-ABL1","volume":"171","author":"Rea","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"2023070520003801200_CIT0030","doi-asserted-by":"crossref","first-page":"106458","DOI":"10.1016\/j.leukres.2020.106458","article-title":"The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase","volume":"98","author":"Manley","year":"2020","journal-title":"Leuk Res"},{"issue":"3","key":"2023070520003801200_CIT0031","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1002\/cam4.5212","article-title":"Asciminib vs bosutinib in CML patients pretreated with &gt;\/=2 tyrosine kinase inhibitors: results from the Japanese subgroup analysis of ASCEMBL study","volume":"12","author":"Yuda","year":"2023","journal-title":"Cancer Med"},{"issue":"17","key":"2023070520003801200_CIT0032","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","article-title":"Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia \u00adchromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood"},{"key":"2023070520003801200_CIT0033","author":"EMA\u2019s Committee for Medicinal Products for Human Use (CHMP)","year":"2015"},{"key":"2023070520003801200_CIT0034","author":"EMA\u2019s Committee for Medicinal Products for Human Use (CHMP)","year":"2013"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/7\/628\/50825921\/oyad119.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/7\/628\/50825921\/oyad119.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T20:01:15Z","timestamp":1688587275000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/7\/628\/7152421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,4]]},"references-count":34,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,5,4]]},"published-print":{"date-parts":[[2023,7,5]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad119","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7,1]]},"published":{"date-parts":[[2023,5,4]]}}}